Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis.

Dysregulated cell growth or differentiation due to misexpression of developmental critical factors seems to be a decisive event in oncogenesis. As osteosarcomas are histologically defined by malignant osteoblasts producing an osteoid component, we prospected in pediatric osteosarcomas treated with OS94 protocol the genomic status of several genes implied in ossification processes. In 91 osteosarcoma cases, we focused on the analysis of the fibroblast growth factor receptors (FGFRs) TWIST, APC, and MET by allelotyping, real-time quantitative polymerase chain reaction, gene sequencing, and protein polymorphism study. Our study supports the frequent role of TWIST, APC, and MET as osteosarcoma markers (50%, 62%, and 50%, respectively). TWIST and MET were mainly found to be deleted, and no additional APC mutation was identified. Surprisingly, FGFRs are abnormal in only < 30%. Most of these factors and their abnormalities seem to be linked more or less to one clinical subgroup, but the most significant correlation is the link of MET, TWIST, and APC abnormalities to a worse outcome and their combination within abnormal tumors. A wider cohort is mandatory to define more robust molecular conclusions, but these results are to be considered as the beginning of a more accurate basis for diagnosis, in search of targeted therapies, and to further characterize prognostic markers.

[1]  M. Gaub,et al.  KIT gene in pediatric osteosarcomas: Could it be a new therapeutic target? , 2007, International journal of cancer.

[2]  D. Vanel,et al.  SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. , 2007, European journal of cancer.

[3]  J. Nährig,et al.  FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  N. Malats,et al.  Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Birchmeier,et al.  Aberrant Wnt/beta-catenin signaling can induce chromosomal instability in colon cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  L. Naldini,et al.  MET overexpression turns human primary osteoblasts into osteosarcomas. , 2006, Cancer research.

[7]  R. Cheney,et al.  FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[8]  C. Hartmann A Wnt canon orchestrating osteoblastogenesis. , 2006, Trends in cell biology.

[9]  Zhixiang Liao,et al.  The Wnt-inducible Transcription Factor Twist1 Inhibits Chondrogenesis* , 2006, Journal of Biological Chemistry.

[10]  M. Heymann,et al.  Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice , 2005, Cancer.

[11]  A. Puisieux,et al.  A twist for survival and cancer progression , 2005, British Journal of Cancer.

[12]  M. Gaub,et al.  Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas , 2005, International journal of cancer.

[13]  C. Eberhart,et al.  The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. , 2005, Cancer research.

[14]  Y. Yen,et al.  Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. , 2005, World journal of gastroenterology.

[15]  D. Silbergeld,et al.  TWIST is expressed in human gliomas and promotes invasion. , 2005, Neoplasia.

[16]  C. Colnot Cellular and molecular interactions regulating skeletogenesis , 2005, Journal of cellular biochemistry.

[17]  Xiaomeng Zhang,et al.  Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. , 2005, Cancer research.

[18]  Carl W. Miller,et al.  Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes. , 2005, Cancer genetics and cytogenetics.

[19]  Wei Liu,et al.  Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. , 2005, Endocrinology.

[20]  M. Ittmann,et al.  The Fibroblast Growth Factor Receptor-4 Arg388 Allele Is Associated with Prostate Cancer Initiation and Progression , 2004, Clinical Cancer Research.

[21]  A. Ullrich,et al.  Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma , 2004, International journal of cancer.

[22]  D. Heymann,et al.  Bisphosphonates: new therapeutic agents for the treatment of bone tumors. , 2004, Trends in molecular medicine.

[23]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[24]  H. Yoshikawa,et al.  Bone morphogenetic proteins in bone tumors , 2004, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[25]  H. Inoue,et al.  Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high‐grade soft tissue sarcoma , 2003, Cancer.

[26]  P. Terrier,et al.  Genetic alterations in primary osteosarcoma from 54 children and adolescents by targeted allelotyping , 2003, British Journal of Cancer.

[27]  J. Helms,et al.  Molecular ontogeny of the skeleton. , 2003, Birth defects research. Part C, Embryo today : reviews.

[28]  Z. Hořejší,et al.  The twist gene is a common target of retroviral integration and transcriptional deregulation in experimental nephroblastoma , 2003, Oncogene.

[29]  H. Höfler,et al.  Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. , 2002, Cancer research.

[30]  P. Ducy Contrôle génétique de la squelettogenèse , 2001 .

[31]  C. Hartmann,et al.  Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2 , 2001, Mechanisms of Development.

[32]  P. Ducy CBFA1: A molecular switch in osteoblast biology , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.

[33]  D. Jacqmin,et al.  Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer. , 2000, Cancer research.

[34]  D. Rice,et al.  Integration of FGF and TWIST in calvarial bone and suture development. , 2000, Development.

[35]  D. Rice,et al.  Molecular mechanisms in calvarial bone and suture development, and their relation to craniosynostosis. , 1999, European journal of orthodontics.

[36]  D. Bishop,et al.  K‐ras mutation and loss of heterozygosity of the adenomatous polyposis coli gene in patients with colorectal adenomas with in situ carcinoma , 1999, Cancer.

[37]  E. Canalis,et al.  Fibroblast growth factor-2 induces hepatocyte growth factor/scatter factor expression in osteoblasts. , 1999, Endocrinology.

[38]  B. Crombrugghe,et al.  Toward understanding SOX9 function in chondrocyte differentiation. , 1998 .

[39]  R. Baron,et al.  Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation , 2005 .

[40]  R. Altman,et al.  Hepatocyte growth factor and its actions in growth plate chondrocytes. , 1996, Bone.

[41]  D. Ornitz,et al.  Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia , 1996, Nature Genetics.

[42]  G. Dorn,et al.  Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. , 1995, Molecular biology of the cell.

[43]  P. Lollini,et al.  The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. , 1995, Oncogene.

[44]  G. Grasselli,et al.  Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. , 2006, European journal of cancer.

[45]  M. Koutsilieris,et al.  Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells. , 2006, Anticancer research.

[46]  G. Gordon,et al.  Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. , 2006, Cancer research.

[47]  K. Ogasawara,et al.  Detection of gene amplification and deletion in high-grade gliomas using a genome DNA microarray (GenoSensor Array 300) , 2006, Brain Tumor Pathology.

[48]  J. Wood Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. , 2000, Medicina.

[49]  V. Lefebvre,et al.  Toward understanding SOX9 function in chondrocyte differentiation. , 1998, Matrix biology : journal of the International Society for Matrix Biology.

[50]  G. Karsenty,et al.  Genetics of skeletogenesis. , 1998, Developmental genetics.

[51]  P. Bénit,et al.  Mutations of the TWIST gene in the Saethre-Chotzene syndrome , 1997, Nature Genetics.